12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Mechanistic Role of mPTP in Ischemia-Reperfusion Injury.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Acute myocardial infarction (MI) is a major cause of death and disability worldwide. The treatment of choice for reducing ischemic injury and limiting infarct size (IS) in patients with ST-segment elevation MI (STEMI) is timely and effective myocardial reperfusion via primary percutaneous coronary intervention (PCI). However, myocardial reperfusion itself may induce further cardiomyocyte death, a phenomenon known as reperfusion injury (RI). The opening of a large pore in the mitochondrial membrane, namely, the mitochondrial permeability transition pore (mPTP), is widely recognized as the final step of RI and is responsible for mitochondrial and cardiomyocyte death. Although myocardial reperfusion interventions continue to improve, there remain no effective therapies for preventing RI due to incomplete knowledge regarding RI components and mechanisms and to premature translations of findings from animals to humans. In the last year, increasing amounts of data describing mPTP components, structure, regulation and function have surfaced. These data may be crucial for gaining a better understanding of RI genesis and for planning future trials evaluating new cardioprotective strategies. In this chapter, we review the role of the mPTP in RI pathophysiology and report on recent studies investigating its structure and components. Finally, we provide a brief overview of principal cardioprotective strategies and their pitfalls.

          Related collections

          Author and article information

          Journal
          Adv. Exp. Med. Biol.
          Advances in experimental medicine and biology
          Springer Nature America, Inc
          0065-2598
          0065-2598
          2017
          : 982
          Affiliations
          [1 ] Department of Morphology, Surgery and Experimental Medicine, Section of General Pathology, Interdisciplinary Center for the Study of Inflammation (ICSI), University of Ferrara, Ferrara, Italy.
          [2 ] Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy.
          [3 ] Cardiovascular Institute, Azienda Ospedaliera Universitaria di Ferrara, Ferrara, Italy.
          [4 ] Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
          [5 ] Department of Biochemistry, Nencki Institute of Experimental Biology, Warsaw, Poland.
          [6 ] Department of Morphology, Surgery and Experimental Medicine, Section of General Pathology, Interdisciplinary Center for the Study of Inflammation (ICSI), University of Ferrara, Ferrara, Italy. paolo.pinton@unife.it.
          [7 ] Laboratory for Technologies of Advanced Therapies (LTTA), University of Ferrara, Ferrara, Italy. paolo.pinton@unife.it.
          Article
          10.1007/978-3-319-55330-6_9
          28551787
          8e74ac55-41a7-4603-b34d-1b125299ccef
          History

          mPTP,Mitochondria,Cardiovascular medicine,Apoptosis,Ischemia-reperfusion injury

          Comments

          Comment on this article